Clinical cases presented here reinforce the hypothesis that GcMaf could become part of anticancer immunotherapeutic regimes.

Abstract Title:

GC protein-derived macrophage-activating factor decreasesα-N-acetylgalactosaminidase levels in advanced cancer patients.

Abstract Source:

Oncoimmunology. 2013 Aug 1 ;2(8):e25769. Epub 2013 Jul 29. PMID: 24179708

Abstract Author(s):

Lynda Thyer, Emma Ward, Rodney Smith, Jacopo Jv Branca, Gabriele Morucci, Massimo Gulisano,  Robert Eslinger, Stefania Pacini

Article Affiliation:

Lynda Thyer

Abstract:

α-N-acetylgalactosaminidase (nagalase) accumulates in the serum of cancer patients and its activity correlates with tumor burden, aggressiveness and clinical disease progression. The administration of GC protein-derived macrophage-activating factor (GcMAF) to cancer patients with elevated levels ofnagalase has been associated with a decrease of serum nagalase activity and with significant clinical benefits. Here, we report the results of the administration of GcMAF to a heterogeneous cohort of patients with histologically diverse, advanced neoplasms, generally considered as”incurable”diseases. In most cases, GcMAF therapy was initiated at late stages of tumor progression. As this is an open-label, non-controlled, retrospective analysis, caution must be employed when establishing cause-effect relationships between the administration GcMAF and disease outcome. However, the response to GcMAF was generally robust and some trends emerged. All patients (n = 20) presented with elevated serum nagalase activity, well above normal values. All patients but one showed a significant decrease of serum nagalase activity upon weekly GcMAF injections. Decreased nagalase activity was associated with improved clinical conditions and no adverse side effects were reported. The observations reported here confirm and extend previous results and pave the way to further studies aimed at assessing the precise role and indications for GcMAF-based anticancer immunotherapy.

Please see this article for a real life story of how Immunotherapy Bulgarian GcMAF works for even the rarest types of cancer.
Study Type : Human Study
Additional Links Nagalase explained: https://healingoracle.ch/2015/06/01/nagalase-in-blood
We do the research you decide,
Love and Light
The Healing Oracle Team
Please join our growing numbers on MeWe: Healing Oracle
Also join us on Twitter | YouTube

Global Petition

Please sign our global petition against enforced vaccinations The intention of this petition is to present 5 million signatures to each President, Prime Minister, Health Minister and heads of state worldwide.
Vaccines are a global problem and need to be tackled on a global level.
If we stand as one, we have a chance of saving the children of the future.

Keep Us Advertising Free

Healing Oracle is made possible by the support of its readers. If you find the posts and resources useful, please consider making a contribution to support us (in any amount) so we can continue to inform and assist people around the world. We feel that giving a voice to those who have transformed their health, or that of a loved one, with alternative treatment is an important mission. Thank you for valuing our work and helping it to continue.

Donate. Should you choose to kindly donate towards our time and efforts, please use the ‘donations’ box above on the top right hand side (on Desktop), or the donations box below (on Mobile)

[social_warfare]

    Leave Your Comment